Drugs / MK-4074
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01431521 | Oct 2011 → Sep 2012 | NAFLD1 | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01431521 ↗ |
| Route | Oral | “orally” NCT01431521 ↗ |